Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 24,862 |
|
|||||
| News | (1) | ||||||
| Day High | 8.5908 | Low High |
|||||
| Day Low | 7.90 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Curis Inc | CRIS | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.37 | -4.35% | 8.13 | 23:00:04 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 8.54 | 7.90 | 8.5908 | 8.13 | 8.50 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 483 | 24,862 | US$ 8.33 | US$ 207,180 | - | 3.80 - 18.00 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:04:01 | 1 | US$ 7.94 | USD |
Curis Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 47.68M | 5.89M | - | 10.02M | -47.41M | -8.04 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Curis News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CRIS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 9.66 | 9.67 | 6.32 | 8.19 | 64,094 | -1.53 | -15.84% |
| 1 Month | 12.66 | 13.00 | 6.32 | 9.41 | 36,253 | -4.53 | -35.78% |
| 3 Months | 10.83 | 17.49 | 6.32 | 12.78 | 31,889 | -2.70 | -24.93% |
| 6 Months | 12.03 | 17.49 | 6.32 | 11.81 | 34,932 | -3.90 | -32.42% |
| 1 Year | 16.00 | 18.00 | 3.80 | 12.49 | 135,949 | -7.87 | -49.19% |
| 3 Years | 166.40 | 180.80 | 3.80 | 59.42 | 1,211,532 | -158.27 | -95.11% |
| 5 Years | 28.60 | 348.00 | 3.80 | 96.91 | 1,569,383 | -20.47 | -71.57% |
Curis Description
| Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. |
